ID   DEAF1_HUMAN             Reviewed;         565 AA.
AC   O75398; A8K1F8; A8K5R8; C7T5V5; O15152; O75399; O75510; O75511; O75512;
AC   O75513; Q9UET1;
DT   13-AUG-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   02-OCT-2024, entry version 221.
DE   RecName: Full=Deformed epidermal autoregulatory factor 1 homolog;
DE   AltName: Full=Nuclear DEAF-1-related transcriptional regulator;
DE            Short=NUDR;
DE   AltName: Full=Suppressin;
DE   AltName: Full=Zinc finger MYND domain-containing protein 5;
GN   Name=DEAF1; Synonyms=SPN, ZMYND5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF ARG-302
RP   AND LYS-304.
RC   TISSUE=Choriocarcinoma;
RX   PubMed=9773984; DOI=10.1210/me.12.10.1619;
RA   Huggenvik J.I., Michelson R.J., Collard M.W., Ziemba A.J., Gurley P.,
RA   Mowen K.A.;
RT   "Characterization of a nuclear deformed epidermal autoregulatory factor-1
RT   (DEAF-1)-related (NUDR) transcriptional regulator protein.";
RL   Mol. Endocrinol. 12:1619-1639(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), VARIANTS VAL-186; ASN-191; ILE-191;
RP   199-TYR--GLU-202 DELINS CYS-ASP-ASN-ASP; ASP-202; LYS-218; 350-ASP--ALA-352
RP   DELINS GLY-GLN-THR; HIS-356; ASN-364; HIS-367; LEU-370; PHE-397; ALA-442;
RP   LYS-449; 451-ARG-SER-452 DELINS GLY-ILE; HIS-468; LEU-479; LYS-498;
RP   ASN-526; LEU-530; 537-GLN-HIS-538 DELINS HIS-LEU; HIS-542; GLY-545 AND
RP   VAL-545, AND ROLE IN NEOPLASIA.
RC   TISSUE=Colon, and Colon adenocarcinoma;
RX   PubMed=11705868;
RA   Manne U., Gary B.D., Oelschlager D.K., Weiss H.L., Frost A.R.,
RA   Grizzle W.E.;
RT   "Altered subcellular localization of suppressin, a novel inhibitor of cell-
RT   cycle entry, is an independent prognostic factor in colorectal
RT   adenocarcinomas.";
RL   Clin. Cancer Res. 7:3495-3503(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Pancreas;
RX   PubMed=19668219; DOI=10.1038/ni.1773;
RA   Yip L., Su L., Sheng D., Chang P., Atkinson M., Czesak M., Albert P.R.,
RA   Collier A.R., Turley S.J., Fathman C.G., Creusot R.J.;
RT   "Deaf1 isoforms control the expression of genes encoding peripheral tissue
RT   antigens in the pancreatic lymph nodes during type 1 diabetes.";
RL   Nat. Immunol. 10:1026-1033(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Mammary gland;
RA   LeBoeuf R.D., Blalock J.E., Tauber J.D.;
RT   "Cloning and sequence analysis of the cDNA for human suppressin (spn).";
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain, and Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=10521432; DOI=10.1074/jbc.274.43.30510;
RA   Michelson R.J., Collard M.W., Ziemba A.J., Persinger J., Bartholomew B.,
RA   Huggenvik J.I.;
RT   "Nuclear DEAF-1-related (NUDR) protein contains a novel DNA binding domain
RT   and represses transcription of the heterogeneous nuclear ribonucleoprotein
RT   A2/B1 promoter.";
RL   J. Biol. Chem. 274:30510-30519(1999).
RN   [8]
RP   FUNCTION OF SAND DOMAIN, AND MUTAGENESIS OF TYR-215; ARG-226; ARG-246;
RP   LYS-250; TRP-252 AND LYS-253.
RX   PubMed=11427895; DOI=10.1038/89675;
RA   Bottomley M.J., Collard M.W., Huggenvik J.I., Liu Z., Gibson T.J.,
RA   Sattler M.;
RT   "The SAND domain structure defines a novel DNA-binding fold in
RT   transcriptional regulation.";
RL   Nat. Struct. Biol. 8:626-633(2001).
RN   [9]
RP   FUNCTION.
RX   PubMed=18826651; DOI=10.1186/1471-213X-8-94;
RA   Barker H.E., Smyth G.K., Wettenhall J., Ward T.A., Bath M.L.,
RA   Lindeman G.J., Visvader J.E.;
RT   "Deaf-1 regulates epithelial cell proliferation and side-branching in the
RT   mammary gland.";
RL   BMC Dev. Biol. 8:94-94(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   DNA-BINDING, IDENTIFICATION IN A COMPLEX WITH XRCC5 AND XRCC6, SUBCELLULAR
RP   LOCATION, AND PHOSPHORYLATION BY DNA-PK COMPLEX.
RX   PubMed=22442688; DOI=10.1371/journal.pone.0033404;
RA   Jensik P.J., Huggenvik J.I., Collard M.W.;
RT   "Deformed epidermal autoregulatory factor-1 (DEAF1) interacts with the Ku70
RT   subunit of the DNA-dependent protein kinase complex.";
RL   PLoS ONE 7:E33404-E33404(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-176 AND THR-432, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, INTERACTION WITH XRCC6, DNA-BINDING, TISSUE SPECIFICITY,
RP   INVOLVEMENT IN VSVS, VARIANTS VSVS TRP-224; SER-228; SER-254 AND PRO-264,
RP   CHARACTERIZATION OF VARIANTS VSVS TRP-224; SER-228; SER-254 AND PRO-264,
RP   AND MUTAGENESIS OF LYS-250 AND LYS-253.
RX   PubMed=24726472; DOI=10.1016/j.ajhg.2014.03.013;
RA   Vulto-van Silfhout A.T., Rajamanickam S., Jensik P.J., Vergult S.,
RA   de Rocker N., Newhall K.J., Raghavan R., Reardon S.N., Jarrett K.,
RA   McIntyre T., Bulinski J., Ownby S.L., Huggenvik J.I., McKnight G.S.,
RA   Rose G.M., Cai X., Willaert A., Zweier C., Endele S., de Ligt J.,
RA   van Bon B.W., Lugtenberg D., de Vries P.F., Veltman J.A., van Bokhoven H.,
RA   Brunner H.G., Rauch A., de Brouwer A.P., Carvill G.L., Hoischen A.,
RA   Mefford H.C., Eichler E.E., Vissers L.E., Menten B., Collard M.W.,
RA   de Vries B.B.;
RT   "Mutations affecting the SAND domain of DEAF1 cause intellectual disability
RT   with severe speech impairment and behavioral problems.";
RL   Am. J. Hum. Genet. 94:649-661(2014).
RN   [14]
RP   STRUCTURE BY NMR OF 496-544 IN COMPLEX WITH ZINC IONS, AND RETRACTED PAPER.
RX   PubMed=16527309; DOI=10.1016/j.jmb.2006.01.087;
RA   Spadaccini R., Perrin H., Bottomley M.J., Ansieau S., Sattler M.;
RT   "Structure and functional analysis of the MYND domain.";
RL   J. Mol. Biol. 358:498-508(2006).
RN   [15]
RP   STRUCTURE BY NMR OF 501-544 IN COMPLEX WITH ZINC IONS, SUBUNIT, INTERACTION
RP   WITH NCOR1 AND NCOR2, AND MUTAGENESIS OF HIS-538.
RX   PubMed=23372760; DOI=10.1371/journal.pone.0054715;
RA   Kateb F., Perrin H., Tripsianes K., Zou P., Spadaccini R., Bottomley M.,
RA   Franzmann T.M., Buchner J., Ansieau S., Sattler M.;
RT   "Structural and functional analysis of the DEAF-1 and BS69 MYND domains.";
RL   PLoS ONE 8:E54715-E54715(2013).
RN   [16]
RP   RETRACTION NOTICE OF PUBMED:16527309.
RX   PubMed=18286714; DOI=10.1016/j.jmb.2008.01.071;
RA   Spadaccini R., Perrin H., Bottomley M.J., Ansieau S., Sattler M.;
RT   "Retraction notice to 'Structure and functional analysis of the MYND
RT   domain' [J. Mol. Biol. (2006) 358, 498-508].";
RL   J. Mol. Biol. 376:1523-1523(2008).
RN   [17]
RP   VARIANT TRP-226.
RX   PubMed=24668509; DOI=10.1002/ajmg.a.36482;
RA   Faqeih E.A., Al-Owain M., Colak D., Kenana R., Al-Yafee Y., Al-Dosary M.,
RA   Al-Saman A., Albalawi F., Al-Sarar D., Domiaty D., Daghestani M., Kaya N.;
RT   "Novel homozygous DEAF1 variant suspected in causing white matter disease,
RT   intellectual disability, and microcephaly.";
RL   Am. J. Med. Genet. A 164A:1565-1570(2014).
RN   [18]
RP   INVOLVEMENT IN VSVS, AND VARIANT SER-228.
RX   PubMed=21076407; DOI=10.1038/ng.712;
RA   Vissers L.E., de Ligt J., Gilissen C., Janssen I., Steehouwer M.,
RA   de Vries P., van Lier B., Arts P., Wieskamp N., del Rosario M.,
RA   van Bon B.W., Hoischen A., de Vries B.B., Brunner H.G., Veltman J.A.;
RT   "A de novo paradigm for mental retardation.";
RL   Nat. Genet. 42:1109-1112(2010).
RN   [19]
RP   INVOLVEMENT IN NEDHELS.
RX   PubMed=26048982; DOI=10.1136/jmedgenet-2015-103083;
RA   Rajab A., Schuelke M., Gill E., Zwirner A., Seifert F.,
RA   Morales Gonzalez S., Knierim E.;
RT   "Recessive DEAF1 mutation associates with autism, intellectual disability,
RT   basal ganglia dysfunction and epilepsy.";
RL   J. Med. Genet. 52:607-611(2015).
CC   -!- FUNCTION: Transcription factor that binds to sequence with multiple
CC       copies of 5'-TTC[CG]G-3' present in its own promoter and that of the
CC       HNRPA2B1 gene. Down-regulates transcription of these genes. Binds to
CC       the retinoic acid response element (RARE) 5'-AGGGTTCACCGAAAGTTCA-3'.
CC       Activates the proenkephalin gene independently of promoter binding,
CC       probably through protein-protein interaction. When secreted, behaves as
CC       an inhibitor of cell proliferation, by arresting cells in the G0 or G1
CC       phase. Required for neural tube closure and skeletal patterning.
CC       Regulates epithelial cell proliferation and side-branching in the
CC       mammary gland. Controls the expression of peripheral tissue antigens in
CC       pancreatic lymph nodes. Isoform 1 displays greater transcriptional
CC       activity than isoform 4. Isoform 4 may inhibit transcriptional activity
CC       of isoform 1 by interacting with isoform 1 and retaining it in the
CC       cytoplasm. Transcriptional activator of EIF4G3.
CC       {ECO:0000269|PubMed:10521432, ECO:0000269|PubMed:11427895,
CC       ECO:0000269|PubMed:11705868, ECO:0000269|PubMed:18826651,
CC       ECO:0000269|PubMed:19668219, ECO:0000269|PubMed:24726472}.
CC   -!- SUBUNIT: Homodimer. Isoform 1 and isoform 4 may form a heterodimer.
CC       Interacts with LMO2 and CLIM2 (By similarity). Interacts with LMO4;
CC       LMO4 blocks export from nucleus (By similarity). May interact with the
CC       corepressors NCOR1 and NCRO2. Identified in a complex with the XRCC5
CC       and XRCC6 heterodimer. Interacts (via the SAND domain) with the DNA-PK
CC       complex subunit XRCC6; the interaction is direct and may be inhibited
CC       by DNA-binding. {ECO:0000250, ECO:0000269|PubMed:16527309,
CC       ECO:0000269|PubMed:22442688, ECO:0000269|PubMed:23372760,
CC       ECO:0000269|PubMed:24726472}.
CC   -!- INTERACTION:
CC       O75398; P42771: CDKN2A; NbExp=2; IntAct=EBI-718185, EBI-375053;
CC       O75398; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-718185, EBI-742887;
CC       O75398; Q14192: FHL2; NbExp=4; IntAct=EBI-718185, EBI-701903;
CC       O75398; P49840: GSK3A; NbExp=3; IntAct=EBI-718185, EBI-1044067;
CC       O75398; P49841: GSK3B; NbExp=2; IntAct=EBI-718185, EBI-373586;
CC       O75398; P51608: MECP2; NbExp=3; IntAct=EBI-718185, EBI-1189067;
CC       O75398; P37840: SNCA; NbExp=3; IntAct=EBI-718185, EBI-985879;
CC       O75398; Q13148: TARDBP; NbExp=3; IntAct=EBI-718185, EBI-372899;
CC       O75398; P12956: XRCC6; NbExp=7; IntAct=EBI-718185, EBI-353208;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus. Cytoplasm. Note=Cytoplasmic
CC       in non-mucinous colorectal carcinoma. When expressed alone, localized
CC       almost exclusively in the nucleus but, when expressed with isoform 4,
CC       nuclear expression decreases to 32% and cytoplasmic expression
CC       increases by 270%.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. Note=Secreted in some cell
CC       types.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted. Note=Secreted in some cell
CC       types.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm. Nucleus. Note=When
CC       expressed alone, localizes mainly in the cytoplasm but, when expressed
CC       with isoform 1, nuclear localization is enhanced.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Hu-DF1;
CC         IsoId=O75398-1; Sequence=Displayed;
CC       Name=2; Synonyms=NUDR8;
CC         IsoId=O75398-3; Sequence=VSP_005967;
CC       Name=3; Synonyms=Suppressin;
CC         IsoId=O75398-4; Sequence=VSP_005966;
CC       Name=4; Synonyms=Hu-DF1-VAR;
CC         IsoId=O75398-5; Sequence=VSP_038701, VSP_038702;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues and cells such as in
CC       peripheral mononuclear cells and hormone-secreting pituitary cells.
CC       Expression in pancreatic lymph nodes of patients with type 1 diabetes
CC       is 20 times higher than in healthy controls. Highly expressed in fetal
CC       and adult brain. {ECO:0000269|PubMed:19668219,
CC       ECO:0000269|PubMed:24726472}.
CC   -!- PTM: May be phosphorylated by DNA-PK complex in a DNA independent
CC       manner (in vitro). {ECO:0000269|PubMed:22442688}.
CC   -!- DISEASE: Vulto-van Silfout-de Vries syndrome (VSVS) [MIM:615828]: An
CC       autosomal dominant disorder characterized by intellectual disability,
CC       poor speech, motor delay, and autistic features. Most patients have
CC       additional non-specific features, including hypotonia and gait
CC       abnormalities, seizures, which may be refractory, high pain threshold,
CC       and sleep disturbances. {ECO:0000269|PubMed:21076407,
CC       ECO:0000269|PubMed:24726472}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Neurodevelopmental disorder with hypotonia, impaired
CC       expressive language, and with or without seizures (NEDHELS)
CC       [MIM:617171]: An autosomal recessive disorder characterized by
CC       psychomotor delay, epilepsy, intellectual disability, speech impairment
CC       and dyskinesia of the limbs. Patients also manifest autistic features
CC       and other behavioral abnormalities. {ECO:0000269|PubMed:26048982}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Defective DEAF1 could confer a growth advantage to the
CC       mutated cells influencing the development and progression of neoplasia,
CC       e.g. in the case of colorectal carcinomas. Subcellular location in
CC       colorectal carcinomas (cytoplasmic or nuclear) is a prognostic factor
CC       that identifies a subgroup of patients with reduced survival. In
CC       addition, changes in the subcellular location correlates with the
CC       proliferative status of the cells.
CC   -!- MISCELLANEOUS: [Isoform 3]: Has no predictable signal peptide.
CC       {ECO:0000305}.
CC   -!- CAUTION: This protein was first known as suppressin (characterized in
CC       bovine neuroendocrine and immune cells). However, according to
CC       PubMed:9773984, it is uncertain whether it corresponds really to the
CC       suppressin also described in Ref.4. DEAF1 has been described as a
CC       nuclear dimeric protein and suppressin as a secreted monomeric protein.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC25718.1; Type=Miscellaneous discrepancy; Note=Several sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=AAC25719.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- SEQUENCE CAUTION: [Isoform 3]:
CC       Sequence=AAC25718.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAC25719.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF049459; AAC79676.1; -; mRNA.
DR   EMBL; AF049460; AAC79677.1; -; mRNA.
DR   EMBL; AF068893; AAC25715.1; -; mRNA.
DR   EMBL; AF068894; AAC25716.1; -; mRNA.
DR   EMBL; AF068895; AAC25717.1; -; mRNA.
DR   EMBL; AF068896; AAC25718.1; ALT_SEQ; mRNA.
DR   EMBL; AF068897; AAC25719.1; ALT_FRAME; mRNA.
DR   EMBL; FJ985253; ACU88060.1; -; mRNA.
DR   EMBL; AF007165; AAB62704.1; -; mRNA.
DR   EMBL; AK291383; BAF84072.1; -; mRNA.
DR   EMBL; AK289873; BAF82562.1; -; mRNA.
DR   EMBL; BC053322; AAH53322.1; -; mRNA.
DR   CCDS; CCDS31327.1; -. [O75398-1]
DR   RefSeq; NP_001280563.1; NM_001293634.1. [O75398-5]
DR   RefSeq; NP_066288.2; NM_021008.3. [O75398-1]
DR   PDB; 2JW6; NMR; -; A=496-544.
DR   PDB; 4A24; NMR; -; A=501-544.
DR   PDB; 5UWW; X-ray; 2.15 A; D=452-469.
DR   PDBsum; 2JW6; -.
DR   PDBsum; 4A24; -.
DR   PDBsum; 5UWW; -.
DR   AlphaFoldDB; O75398; -.
DR   BMRB; O75398; -.
DR   SMR; O75398; -.
DR   BioGRID; 115777; 44.
DR   CORUM; O75398; -.
DR   ELM; O75398; -.
DR   IntAct; O75398; 31.
DR   MINT; O75398; -.
DR   STRING; 9606.ENSP00000371846; -.
DR   GlyGen; O75398; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O75398; -.
DR   PhosphoSitePlus; O75398; -.
DR   BioMuta; DEAF1; -.
DR   jPOST; O75398; -.
DR   MassIVE; O75398; -.
DR   PaxDb; 9606-ENSP00000371846; -.
DR   PeptideAtlas; O75398; -.
DR   ProteomicsDB; 49968; -. [O75398-1]
DR   ProteomicsDB; 49969; -. [O75398-3]
DR   ProteomicsDB; 49970; -. [O75398-4]
DR   ProteomicsDB; 49971; -. [O75398-5]
DR   Antibodypedia; 9854; 368 antibodies from 31 providers.
DR   DNASU; 10522; -.
DR   Ensembl; ENST00000382409.4; ENSP00000371846.3; ENSG00000177030.19. [O75398-1]
DR   GeneID; 10522; -.
DR   KEGG; hsa:10522; -.
DR   MANE-Select; ENST00000382409.4; ENSP00000371846.3; NM_021008.4; NP_066288.2.
DR   UCSC; uc001lqq.2; human. [O75398-1]
DR   AGR; HGNC:14677; -.
DR   CTD; 10522; -.
DR   DisGeNET; 10522; -.
DR   GeneCards; DEAF1; -.
DR   HGNC; HGNC:14677; DEAF1.
DR   HPA; ENSG00000177030; Tissue enriched (brain).
DR   MalaCards; DEAF1; -.
DR   MIM; 602635; gene.
DR   MIM; 615828; phenotype.
DR   MIM; 617171; phenotype.
DR   neXtProt; NX_O75398; -.
DR   OpenTargets; ENSG00000177030; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   Orphanet; 468620; Intellectual disability-epilepsy-extrapyramidal syndrome.
DR   Orphanet; 819; Smith-Magenis syndrome.
DR   PharmGKB; PA27234; -.
DR   VEuPathDB; HostDB:ENSG00000177030; -.
DR   eggNOG; KOG4333; Eukaryota.
DR   GeneTree; ENSGT00940000159701; -.
DR   HOGENOM; CLU_039056_1_0_1; -.
DR   InParanoid; O75398; -.
DR   OMA; KDHQHSC; -.
DR   OrthoDB; 5314634at2759; -.
DR   PhylomeDB; O75398; -.
DR   TreeFam; TF325664; -.
DR   PathwayCommons; O75398; -.
DR   SignaLink; O75398; -.
DR   SIGNOR; O75398; -.
DR   BioGRID-ORCS; 10522; 13 hits in 1177 CRISPR screens.
DR   ChiTaRS; DEAF1; human.
DR   EvolutionaryTrace; O75398; -.
DR   GenomeRNAi; 10522; -.
DR   Pharos; O75398; Tbio.
DR   PRO; PR:O75398; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O75398; protein.
DR   Bgee; ENSG00000177030; Expressed in amygdala and 98 other cell types or tissues.
DR   ExpressionAtlas; O75398; baseline and differential.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0048706; P:embryonic skeletal system development; ISS:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; TAS:ProtInc.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0001843; P:neural tube closure; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0033599; P:regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   Gene3D; 6.10.140.2220; -; 1.
DR   Gene3D; 3.10.390.10; SAND domain-like; 1.
DR   InterPro; IPR010919; SAND-like_dom_sf.
DR   InterPro; IPR000770; SAND_dom.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10237:SF13; DEFORMED EPIDERMAL AUTOREGULATORY FACTOR 1 HOMOLOG; 1.
DR   PANTHER; PTHR10237; DEFORMED EPIDERMAL AUTOREGULATORY FACTOR 1 HOMOLOG SUPPRESSIN; 1.
DR   Pfam; PF01342; SAND; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   SMART; SM00258; SAND; 1.
DR   SUPFAM; SSF144232; HIT/MYND zinc finger-like; 1.
DR   SUPFAM; SSF63763; SAND domain-like; 1.
DR   PROSITE; PS50864; SAND; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Developmental protein;
KW   Disease variant; DNA-binding; Epilepsy; Intellectual disability;
KW   Metal-binding; Neurogenesis; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Secreted; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..565
FT                   /note="Deformed epidermal autoregulatory factor 1 homolog"
FT                   /id="PRO_0000074084"
FT   DOMAIN          193..273
FT                   /note="SAND"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00185"
FT   ZN_FING         504..540
FT                   /note="MYND-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   REGION          34..62
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          162..190
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          403..478
FT                   /note="Interaction with LMO4"
FT                   /evidence="ECO:0000250"
FT   MOTIF           301..316
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   BINDING         504
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         507
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         515
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         518
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         524
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         528
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         536
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   BINDING         540
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00134"
FT   MOD_RES         171
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z1T5"
FT   MOD_RES         176
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         179
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z1T5"
FT   MOD_RES         432
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         448
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88450"
FT   VAR_SEQ         1..68
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11705868,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_005966"
FT   VAR_SEQ         15..29
FT                   /note="EAAAVAAAAAVAAAA -> D (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9773984"
FT                   /id="VSP_005967"
FT   VAR_SEQ         223..333
FT                   /note="GRGRCIKQGENWYSPTEFEAMAGRASSKDWKRSIRYAGRPLQCLIQDGILNP
FT                   HAASCTCAACCDDMTLSGPVRLFVPYKRRKKENELPTTPVKKDSPKNITLLPATAATTF
FT                   -> WDLKPSRCLLHLCCLLRRHDLI (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:19668219"
FT                   /id="VSP_038701"
FT   VAR_SEQ         501
FT                   /note="E -> EVIHPPRLPKVLGLQ (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:19668219"
FT                   /id="VSP_038702"
FT   VARIANT         186
FT                   /note="E -> V (in a primary colorectal cancer;
FT                   dbSNP:rs751727919)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013725"
FT   VARIANT         191
FT                   /note="K -> I (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013726"
FT   VARIANT         191
FT                   /note="K -> N (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013727"
FT   VARIANT         199..202
FT                   /note="YDSE -> CDND (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013728"
FT   VARIANT         202
FT                   /note="E -> D (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013729"
FT   VARIANT         218
FT                   /note="R -> K (in a primary colorectal cancer;
FT                   dbSNP:rs1127312)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013730"
FT   VARIANT         224
FT                   /note="R -> W (in VSVS; loss of DEAF1-promoter repression;
FT                   loss of transcriptional activation of EIF4G3; loss of DNA
FT                   binding; decreased interaction with XRCC6;
FT                   dbSNP:rs587777408)"
FT                   /evidence="ECO:0000269|PubMed:24726472"
FT                   /id="VAR_071371"
FT   VARIANT         226
FT                   /note="R -> W (in dbSNP:rs587777623)"
FT                   /evidence="ECO:0000269|PubMed:24668509"
FT                   /id="VAR_071372"
FT   VARIANT         228
FT                   /note="I -> S (in VSVS; loss of DEAF1-promoter repression;
FT                   loss of transcriptional activation of EIF4G3; loss of DNA
FT                   binding; loss of interaction with XRCC6;
FT                   dbSNP:rs587777406)"
FT                   /evidence="ECO:0000269|PubMed:21076407,
FT                   ECO:0000269|PubMed:24726472"
FT                   /id="VAR_065089"
FT   VARIANT         254
FT                   /note="R -> S (in VSVS; loss of DEAF1-promoter repression;
FT                   gain of transcriptional activation of EIF4G3; a 9-fold
FT                   reduction in DNA binding; dbSNP:rs587777409)"
FT                   /evidence="ECO:0000269|PubMed:24726472"
FT                   /id="VAR_071373"
FT   VARIANT         264
FT                   /note="Q -> P (in VSVS; loss of DEAF1-promoter repression;
FT                   loss of transcriptional activation of EIF4G3; loss of DNA
FT                   binding; loss of interaction with XRCC6;
FT                   dbSNP:rs587777407)"
FT                   /evidence="ECO:0000269|PubMed:24726472"
FT                   /id="VAR_071374"
FT   VARIANT         350..352
FT                   /note="DRA -> GQT (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013731"
FT   VARIANT         356
FT                   /note="E -> H (in a primary colorectal cancer; requires 2
FT                   nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013732"
FT   VARIANT         364
FT                   /note="S -> N (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013733"
FT   VARIANT         367
FT                   /note="Q -> H (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013734"
FT   VARIANT         370
FT                   /note="V -> L (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013735"
FT   VARIANT         397
FT                   /note="Y -> F (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013736"
FT   VARIANT         442
FT                   /note="V -> A (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013737"
FT   VARIANT         449
FT                   /note="E -> K (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013738"
FT   VARIANT         451..452
FT                   /note="RS -> GI (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013739"
FT   VARIANT         468
FT                   /note="Q -> H (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013740"
FT   VARIANT         479
FT                   /note="H -> L (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013741"
FT   VARIANT         498
FT                   /note="E -> K (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013742"
FT   VARIANT         526
FT                   /note="T -> N (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013743"
FT   VARIANT         530
FT                   /note="R -> L (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013744"
FT   VARIANT         537..538
FT                   /note="QH -> HL (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013745"
FT   VARIANT         542
FT                   /note="Q -> H (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013746"
FT   VARIANT         545
FT                   /note="A -> G (in a primary colorectal cancer;
FT                   dbSNP:rs34114147)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013747"
FT   VARIANT         545
FT                   /note="A -> V (in a primary colorectal cancer)"
FT                   /evidence="ECO:0000269|PubMed:11705868"
FT                   /id="VAR_013748"
FT   MUTAGEN         215
FT                   /note="Y->Q: Reduces transcription activation"
FT                   /evidence="ECO:0000269|PubMed:11427895"
FT   MUTAGEN         226
FT                   /note="R->A: Reduces transcription activation"
FT                   /evidence="ECO:0000269|PubMed:11427895"
FT   MUTAGEN         246
FT                   /note="R->A: Reduces transcription activation"
FT                   /evidence="ECO:0000269|PubMed:11427895"
FT   MUTAGEN         250
FT                   /note="K->A: Abolishes DNA-binding. Loss of DEAF1-promoter
FT                   repression; when associated with A-253. Loss of
FT                   transcriptional activation of EIF4G3; when associated with
FT                   A-253. Loss of interaction with XRCC6; when associated with
FT                   A-253. Loss of DNA binding; when associated with A-253"
FT                   /evidence="ECO:0000269|PubMed:11427895,
FT                   ECO:0000269|PubMed:24726472"
FT   MUTAGEN         252
FT                   /note="W->Q: Abolishes DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:11427895"
FT   MUTAGEN         253
FT                   /note="K->A: Abolishes DNA-binding. oss of DEAF1-promoter
FT                   repression; when associated with A-250. Loss of
FT                   transcriptional activation of EIF4G3; when associated with
FT                   A-250. Loss of interaction with XRCC6; when associated with
FT                   A-250. Loss of DNA binding; when associated with A-250"
FT                   /evidence="ECO:0000269|PubMed:11427895,
FT                   ECO:0000269|PubMed:24726472"
FT   MUTAGEN         302
FT                   /note="R->T: Abolishes nuclear localization"
FT                   /evidence="ECO:0000269|PubMed:9773984"
FT   MUTAGEN         304
FT                   /note="K->T: Abolishes nuclear localization"
FT                   /evidence="ECO:0000269|PubMed:9773984"
FT   MUTAGEN         538
FT                   /note="H->S: No effect on folding of MYND-type zinc finger"
FT                   /evidence="ECO:0000269|PubMed:23372760"
FT   CONFLICT        65
FT                   /note="A -> E (in Ref. 3; ACU88060)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        72
FT                   /note="E -> D (in Ref. 4; AAB62704)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        166
FT                   /note="P -> Q (in Ref. 3; ACU88060)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="A -> T (in Ref. 4; AAB62704)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        294
FT                   /note="V -> L (in Ref. 4; AAB62704)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        399
FT                   /note="D -> G (in Ref. 3; ACU88060)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        522
FT                   /note="N -> K (in Ref. 4; AAB62704)"
FT                   /evidence="ECO:0000305"
FT   HELIX           456..463
FT                   /evidence="ECO:0007829|PDB:5UWW"
FT   STRAND          505..510
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   STRAND          512..514
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   TURN            516..518
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   STRAND          520..525
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   HELIX           526..532
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   TURN            533..535
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   HELIX           536..538
FT                   /evidence="ECO:0007829|PDB:2JW6"
FT   TURN            539..541
FT                   /evidence="ECO:0007829|PDB:2JW6"
SQ   SEQUENCE   565 AA;  59327 MW;  3BDFEDBF6AD4BDDE CRC64;
     MEDSDSAAKQ LGLAEAAAVA AAAAVAAAAA AAAGGEAEEP VLSRDEDSEE DADSEAERET
     PRVTAVAVMA AEPGHMDMGA EALPGPDEAA AAAAFAEVTT VTVANVGAAA DNVFTTSVAN
     AASISGHVLS GRTALQIGDS LNTEKATLIV VHTDGSIVET TGLKGPAAPL TPGPQSPPTP
     LAPGQEKGGT KYNWDPSVYD SELPVRCRNI SGTLYKNRLG SGGRGRCIKQ GENWYSPTEF
     EAMAGRASSK DWKRSIRYAG RPLQCLIQDG ILNPHAASCT CAACCDDMTL SGPVRLFVPY
     KRRKKENELP TTPVKKDSPK NITLLPATAA TTFTVTPSGQ ITTSGALTFD RASTVEATAV
     ISESPAQGDV FAGATVQEAS VQPPCRASHP EPHYPGYQDS CQIAPFPEAA LPTSHPKIVL
     TSLPALAVPP PTPTKAAPPA LVNGLELSEP RSWLYLEEMV NSLLNTAQQL KTLFEQAKHA
     STYREAATNQ AKIHADAERK EQSCVNCGRE AMSECTGCHK VNYCSTFCQR KDWKDHQHIC
     GQSAAVTVQA DEVHVAESVM EKVTV
//
